ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 12 of 57
УЖМБС 2020, 5(1): 85–90
Experimental Medicine and Morphology

The Influence of Phetoplacental Failure on the State of the Fetus depending on the Age of the Mother

Seliukova N. Yu. 1,2

The purpose of this study was to study the morphofunctional state of the fetoplacental complex with experimental fetoplacental insufficiency in female rats depending on the age of the animals on the background of the new pharmaceutical composition. Material and methods. The study was conducted on healthy adult females of Wistar rats, young (3-4 months) and mature (8-10 months) of reproductive age. There were 8 groups of 7 pregnant females in each age group. The first two groups were intact animals of the appropriate age. The 3rd and 4th groups of females were with experimental fetoplacental insufficiency. For the simulation of fetoplacental insufficiency females from 12 to 18 days of pregnancy subcutaneously were administered 50 % of oil solution of tetrachloromethane at a dose of 2 ml/kg body weight. The 5th and 6th groups consisted of animals with experimental fetoplacental insufficiency and supplementation to the diet pharmaceutical composition depending on the weight of the females from the 11th to 19th day of pregnancy. The last two groups included females with fetoplacental insufficiency + comparison drug dipyridamole. Results and discussion. On the 20th day of pregnancy, females of all groups were decapitated, and fetuses were removed from the uterus together with the placenta and determined the sex of rats. Next, they were weighed and the craniocaudal size was measured. Females of young reproductive age decreased all morphometric parameters of the placenta and fetus on the background of experimental fetoplacental insufficiency, both in the female and male fetuses. We also observed fetuses irrespective of sex of hemorrhage or hematoma in different parts of the body. After correction of this condition with the pharmaceutical composition, we observed normalization of all indicators in the fetuses of both sexes. In the study of females of mature reproductive age, we observed a somewhat different picture regarding the effect of fetoplacental insufficiency on morphometric parameters. Thus, in the female fetus placental weight did not change, but all other indicators decreased significantly. In this case, the pharmaceutical composition did not work; the indicators were as low as in the group with pathology. There were almost no changes in male offspring. Conclusion. Thus, fetoplacental insufficiency affected the morphofunctional state of the fetoplacental complex, namely, it led to a decrease in all weight and size indicators in females of young reproductive age. In adulthood, the impact of fetoplacental insufficiency was negatively reflected in female fetuses, with male fetuses remaining almost unchanged. The pharmaceutical composition positively affected the placenta and fetus in young females on the background of fetoplacental insufficiency.

Keywords: fetoplacental insufficiency, maternal age, female and male fetuses, pharmaceutical composition, dipyridamole

Full text: PDF (Ukr) 217K

  1. Arabin B, Baschat AA. Pregnancy: an underutilized window of opportunity to improve long-term maternal and infant health-an appeal for continuous family care and interdisciplinary communication. Front Pediatr. 2017; 5: 69.
  2. Barker DJ, Thornburg KL. Placental programming of chronic diseases, cancer and lifespan: a review. Placenta. 2013; 34: 841–5.
  3. Bokslag A, van Weissenbruch M, Mol BW, de Groot CJ. Preeclampsia; short and long-term consequences for mother and neonate. Early Hum. Dev. 2016; 102: 47–50.
  4. Burton GJ, Fowden AL, Thornburg KL. Placental origins of Chronic disease. Physiol Rev. 2016; 96: 1509–65.
  5. Filippov OS, Kazanceva AA. Prognosticheskaja znachimost' razlichnyh metodov diagnostiki fetoplacentarnoj nedostatochnosti. Problemy Reprodukcii. 2007; 3: 60–3. [Russian]
  6. Ghidini A. Idiopathic fetal growth restriction: a pathophysiologic approach. Obstet. Gynecol. Surv. 1996; 51(6): 376–82.
  7. Jakovljeva LV, Zajchenko GV, Cypkun AG, et al. Doklinichne vyvchennja likars'kyh zasobiv, pryznachenyh dlja likuvannja placentarnoi dysfunkcii. Metodychni rekomendacii. Kyiv; 2009. 61 p. [Ukrainian]
  8. Kalinovs'ka IV. Osoblyvosti gormonal'noi' aktyvnosti FPK u vagitnyh za umov rozvytku placentarnoi' nedostatnosti. Klinichna ta eksperymental'na patologija. 2007; 6(2): 42–4. [Ukrainian]
  9. Kuz'mina IJu, Kuz'mina OA. Pol' systemy gemostazu v patogenezi rozvytku placentarnoi' dysfunkcii'. Mizhnarodnyj Medychnyj Zhurnal. 2016; 3: 29–31. [Ukrainian]
  10. Nakaz № 1287 vid 19.11.2012. Polozhennja pro Komitet z pytan etyky (bioetyky). Available from: normativno-pravova-baza/ [Ukrainian]
  11. Stasenko T. Zdorov’ja ditej – zavdannja vsijei' medychnoi' spil'noty. Ukrai'ns'kyj medychnyj chasopys. 2016; 3(113). [Ukrainian]
  12. Verhovna Rada Ukrai'ny. Jevropejs'ka konvencija pro zahyst hrebetnyh tvaryn, shho vykorystovujut'sja dlja doslidnyc'kyh abo inshyh naukovyh cilej vid 18.03.1986. Available from: main?find=1&sp=i&user=c393&text=%F2%E2%E0. [Ukrainian]